Drug Profile

Mifepristone - Corcept Therapeutics

Alternative Names: C 1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU 38486; RU-486

Latest Information Update: 23 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roussel Uclaf; Stanford University
Developer Corcept Therapeutics; Danco Laboratories; Population Council (USA); pSivida; Stanford University; University of Chicago
Class Abortifacients; Antidementias; Antidepressants; Antiglaucomas; Antineoplastics; Antiprogestogens; Antipsychotics; Antivirals; Dimethylamines; Estrenes; Eye disorder therapies; Obesity therapies; Oral contraceptives; Small molecules; Smoking cessation therapies
Mechanism of Action Glucocorticoid receptor antagonists; Progesterone receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cushing syndrome
New Molecular Entity Yes

Marketed Cushing syndrome; Induced abortion
Phase II Alcoholism; Breast cancer; Major depressive disorder
Phase I/II Prostate cancer
No development reported Central serous chorioretinopathy; Non-small cell lung cancer; Smoking withdrawal
Discontinued Alzheimer's disease; Obesity; Ocular hypertension; Psychotic affective disorders

19 Feb 2026 The United States Court of Appeals for the Federal Circuit reports that Teva’s proposed generic Korlym^® does not infringe two Corcept patents covering methods for safely co‑administering Korlym with CYP3A4 inhibitors
04 Jan 2024 The U.S. Court for the District of New Jersey rules that Teva Pharmaceuticals does not infringe any asserted claims of Corcept Therapeutics patent no. 10 195 214 and 10 842 800 in the USA
02 Jun 2023 Interim adverse events and efficacy data from a phase-II trial in Breast cancer presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com